PTCT insider trade: 3,375 shares sold, 3,375-share option acquired
Rhea-AI Filing Summary
PTC Therapeutics insider Mark Elliott Boulding, Executive Vice President and Chief Legal Officer, reported transactions on 10/07/2025 under a written Rule 10b5-1 plan adopted on 12/05/2024. He acquired a stock option for 3,375 shares with an exercise price of $38.10 and an expiration date of 01/06/2032. On the same date he sold a total of 3,375 common shares in three weighted-average-price tranches for aggregate proceeds at weighted prices of $62.89, $63.80, and $64.97 (ranges disclosed per tranche). After these transactions he beneficially owned 103,901 shares.
Positive
- Transactions executed under a written Rule 10b5-1 plan adopted on 12/05/2024
- Acquisition of a long-dated stock option for 3,375 shares at an exercise price of $38.10 (expiring 01/06/2032)
- Post-transaction beneficial ownership remains substantial at 103,901 shares
Negative
- Officer sold 3,375 shares on 10/07/2025, which reduces direct shareholdings
- Sales executed at prices notably above the option exercise price (weighted averages of $62.89, $63.80, and $64.97) which may crystallize tax or diversification outcomes
Insights
TL;DR: An officer used a 10b5-1 plan to sell shares while taking new option-based compensation.
Boulding reported concurrent sales of 3,375 common shares and the acquisition of a 3,375-share stock option on 10/07/2025. The option has a $38.10 exercise price and expires on 01/06/2032, and vests per the original grant schedule from 01/07/2022.
The sales were made under a written Rule 10b5-1 plan established on 12/05/2024, which provides an affirmative defense for preplanned trades; monitor any future amendments or additional filings that change beneficial ownership or option holdings within the next 12 months.
TL;DR: Transactions appear executed under a documented compliance plan with detailed price ranges disclosed.
The filing discloses sales executed in multiple tranches at weighted average prices: $62.89, $63.80, and $64.97, with underlying trade price ranges provided for each tranche. The reporting person offers to provide split trade details upon request by regulators or the issuer.
Because the plan date (12/05/2024) precedes the transaction date, these trades align with the mechanics of a 10b5-1 program; compliance observers would watch for additional Form 4s showing further plan-driven activity in the next quarter.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 3,375 | $0.00 | -- |
| Exercise | Common Stock | 3,375 | $38.10 | $129K |
| Sale | Common Stock | 1,757 | $62.89 | $110K |
| Sale | Common Stock | 1,306 | $63.80 | $83K |
| Sale | Common Stock | 312 | $64.97 | $20K |
Footnotes (1)
- This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $62.36 to $63.28 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $63.36 to $64.25 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.56 to $65.01 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023.
